Skip to main content

Advertisement

SpringerLink
Log in

Antikörper-Wirkstoff-Konjugate beim metastasierten Mammakarzinom

Eine vielversprechende Behandlungsstrategie

Antibody–drug conjugates in metastatic breast cancer

A promising treatment strategy

  • Leitthema
  • Published:
Die Onkologie Aims and scope

Zusammenfassung

Hintergrund

Molekulare Faktoren spielen eine wichtige Rolle bei der Entwicklung zielgerichteter Therapien für das metastasierte Mammakarzinom.

Ziel

Neue spezifische und zielgerichtete Therapien beim metastasierten Mammakarzinom sollten vorgestellt werden.

Material und Methoden

Dazu wurden neueste Erkenntnisse über die Therapie mit Antikörper-Wirkstoff-Konjugaten (ADC) ausgewertet.

Ergebnisse

Längeres progressionsfreies Überleben, besseres Gesamtüberleben sowie ein besserer therapeutischer Index durch ADC zeigten sich im Vergleich zu herkömmlichen Chemotherapien.

Schlussfolgerung

ADC haben das Potenzial, das Überleben von Patientinnen mit metastasiertem Mammakarzinom zu verbessern.

Abstract

Background

Molecular factors play a crucial role in the development of targeted therapies for metastatic breast cancer.

Objective

This study aimed to explore new specific and targeted therapies for metastatic breast cancer.

Materials and methods

The latest findings on treatment of metastatic breast cancer with antibody–drug conjugates (ADC) are presented.

Results

Prolonged progression-free survival, improved overall survival, and a lower side effect profile with ADCs compared to conventional chemotherapy could be shown.

Conclusion

ADCs have the potential to enhance survival of patients with metastatic breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. 1909-karzinomforschung.

  2. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. https://doi.org/10.1056/NEJM200103153441101

    Article  CAS  PubMed  Google Scholar 

  3. Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783–1791. https://doi.org/10.1056/NEJMoa1209124

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. André F, Park HY, Kim S‑B et al (2023) Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 401(10390):1773–1785. https://doi.org/10.1016/S0140-6736(23)00725-0

    Article  PubMed  Google Scholar 

  5. Cortés J, Kim S‑B, Chung W‑P et al (2022) Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 386(12):1143–1154. https://doi.org/10.1056/NEJMoa2115022

    Article  PubMed  Google Scholar 

  6. Hurvitz SA, Hegg R, Chung W‑P et al (2023) Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 401(10371):105–117. https://doi.org/10.1016/S0140-6736(22)02420-5

    Article  CAS  PubMed  Google Scholar 

  7. Tarantino P, Hamilton E, Tolaney SM et al (2020) HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol 38(17):1951–1962. https://doi.org/10.1200/JCO.19.02488

    Article  CAS  PubMed  Google Scholar 

  8. Modi S, Jacot W, Yamashita T et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9–20. https://doi.org/10.1056/NEJMoa2203690

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bardia A, Tolaney SM, Punie K et al (2021) Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol 32(9):1148–1156. https://doi.org/10.1016/j.annonc.2021.06.002

    Article  CAS  PubMed  Google Scholar 

  10. Loibl S, Loirat D, Tolaney SM et al (2023) Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. Eur J Cancer 178:23–33. https://doi.org/10.1016/j.ejca.2022.10.003

    Article  CAS  PubMed  Google Scholar 

  11. Rugo HS, Tolaney SM, Loirat D et al (2022) Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer 8(1):98. https://doi.org/10.1038/s41523-022-00467-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Rugo HS, Bardia A, Marmé F et al (2023) Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 402(10411):1423–1433. https://doi.org/10.1016/S0140-6736(23)01245-X

    Article  CAS  PubMed  Google Scholar 

  13. Rugo HS, Bardia A, Marmé F et al (2022) Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2‑negative metastatic breast cancer. J Clin Oncol 40(29):3365–3376. https://doi.org/10.1200/JCO.22.01002

    Article  CAS  PubMed  Google Scholar 

  14. Schmid P, Cortés J, Marmé F et al (2022) 214MO sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROpiCS-02 study. Ann Oncol 33:S635–S636. https://doi.org/10.1016/j.annonc.2022.07.253

    Article  Google Scholar 

  15. Rugo H, Bardia A, Marmé F et al (2023) Abstract GS1-11: sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC): efficacy by trop‑2 expression in the TROPiCS-02 study of patients (pts) with HR+/HER2− metastatic breast cancer (mBC). Cancer Res 83(5):GS1-11. https://doi.org/10.1158/1538-7445.SABCS22-GS1-11

    Article  Google Scholar 

  16. Marmé F, Bardia A, Rugo H et al (2023) Abstract P4-07-65: effect of sacituzumab govitecan vs chemotherapy in HR+/HER2− metastatic breast cancer: patient-reported outcomes from the TROPiCS-02 trial. Cancer Res 83(5):P4-07-65. https://doi.org/10.1158/1538-7445.SABCS22-P4-07-65

    Article  Google Scholar 

  17. Bardia A, Jhaveri K, Kalinsky K et al (2023) TROPION-breast01: datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2− breast cancer. Ann Oncol 34(2):S1254–S1335. https://doi.org/10.1016/annonc/annonc1358

    Article  Google Scholar 

  18. Bardia A, Punie K, Barrios CH et al (2022) 275TiP ASCENT-03: phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in first-line (1L) metastatic triple-negative breast cancer (mTNBC). Ann Oncol 33:S663–S664. https://doi.org/10.1016/j.annonc.2022.07.1859

    Article  Google Scholar 

  19. Tolaney SM, de Azambuja E, Emens LA et al (2022) 276TiP ASCENT-04/KEYNOTE-D19: phase III study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician’s choice (TPC) plus pembro in first-line (1L) programmed death-ligand 1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC). Ann Oncol 33:S664–S665. https://doi.org/10.1016/j.annonc.2022.07.1860

    Article  Google Scholar 

  20. ClinicalTrials.gov (2024) Study details | Study of trastuzumab deruxtecan (T-DXd) vs investigator’s choice chemotherapy in HER2-low, hormone receptor positive, metastatic breast cancer. https://clinicaltrials.gov/study/NCT04494425. Zugegriffen: 11. Jan. 2024

  21. ClinicalTrials.gov (2024) Study details | Study of sacituzumab govitecan versus treatment of physician’s choice in patients with hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) metastatic breast cancer who have received endocrine therapy. https://clinicaltrials.gov/study/NCT05840211. Zugegriffen: 11. Jan. 2024

  22. (2023) Destiny breast-12. DESTINY BREAST-12 study. https://destinybreast12.com/. Zugegriffen: 11. Jan. 2024

  23. (2018) T‑DXd clinical trial for HER2 positive metastatic breast cancer: DESTINY breast-09. https://careboxhealth.com/. Zugegriffen: 11. Jan. 2024

  24. Dent RA, Cescon DW, Bachelot T et al (2023) TROPION-breast02: datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol 19(35):2349–2359. https://doi.org/10.2217/fon-2023-0228

    Article  CAS  PubMed  Google Scholar 

  25. Banerji U, van Herpen CML, Saura C et al (2019) Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 20(8):1124–1135. https://doi.org/10.1016/S1470-2045(19)30328-6

    Article  CAS  PubMed  Google Scholar 

  26. Wei Y, Zhang R, Yu C et al (2023) Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center’s real-world study. Front Pharmacol 14:1230395. https://doi.org/10.3389/fphar.2023.1230395

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Li Y, Zhang J, Cai Z et al (2023) Disitamab vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review. Front Oncol 13:1286392. https://doi.org/10.3389/fonc.2023.1286392

    Article  PubMed  PubMed Central  Google Scholar 

  28. Krop IE, Kim S‑B, Martin AG et al (2017) Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol 18(6):743–754. https://doi.org/10.1016/S1470-2045(17)30313-3

    Article  CAS  PubMed  Google Scholar 

  29. Krop IE, Kim S‑B, González-Martín A et al (2014) Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 15(7):689–699. https://doi.org/10.1016/S1470-2045(14)70178-0

    Article  CAS  PubMed  Google Scholar 

  30. Bardia A, Hurvitz SA, Tolaney SM et al (2021) Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 384(16):1529–1541. https://doi.org/10.1056/NEJMoa2028485

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsmedizin, Johannes Gutenberg-Universität, Langenbeckstr. 1, 55131, Mainz, Deutschland

    Maria Schröder &  Marcus Schmidt

  2. Universitätsfrauenklinik Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Deutschland

    Frederik Marmé

Authors
  1. Maria Schröder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcus Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frederik Marmé
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcus Schmidt.

Ethics declarations

Interessenkonflikt

M. Schröder gibt an, dass kein Interessenkonflikt besteht. M. Schmidt war als Berater für Astra Zeneca, BioNTech, Eisai, Daiichi Sankyo, GILEAD, Lilly, Molecular Health, Novartis, Pantarhei Bioscience, Pfizer, Pierre Fabre, Roche und Seagen tätig. Forschungsunterstützung durch AstraZeneca, BioNTech, Eisai, Genentech, German Breast Group (GBG), Novartis, Palleos, Pantarhei Bioscience, Pfizer, Pierre-Fabre, Roche und Seagen. Patente: EP2390370B1; EP2951317B1. F. Marmé war als Berater für folgende Firmen tätig, bzw. erhielt Vortragshonorare: AstraZeneca, Daiichi Sankyo, Gilead, Seagen, Roche, Novartis, Pfizer, Pierre-Fabre, Stemline Menarini, Clovis, GSK, Eisai, Myriad Genetics, Lilly. Forschungsunterstützung durch AstraZeneca, German Breast Group (GBG), AGO Research, NOGGO e. V., MEDSIR, Roche, Novartis, MSD, GSK, Lilly, Gilead, Seagen.

Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Hinweis des Verlags

Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schröder, M., Schmidt, M. & Marmé, F. Antikörper-Wirkstoff-Konjugate beim metastasierten Mammakarzinom. Onkologie 30, 479–484 (2024). https://doi.org/10.1007/s00761-024-01491-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-024-01491-5

Schlüsselwörter

Keywords

Search

Navigation